Edoxaban is administered once daily, whereas the approved pediatric dosing for other direct oral anticoagulants (DOACs) ranges from twice daily to three times per day, he noted.

Edoxaban, an oral anticoagulant, was equally or more effective than warfarin in reducing the risk of stroke and blood clots for patients after heart valve replacement surgery, according to ...

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. New England Journal of Medicine, 2021; DOI: 10.1056/NEJMoa2111016; Cite This Page: MLA; APA; Chicago; ...

Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF). It is also used to ...

We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled, event-driven trial to compare a once-daily 15-mg dose of edoxaban with placebo in elderly Japanese patients (≥ ...

However, major bleeding rates were lower for apixaban, driven by differences in gastrointestinal bleeding and other nonspecified bleeding (45.57 vs 31.21 per 1,000 person-years; adjusted HR 1.42 ...

Edoxaban was found to be noninferior to warfarin in patients with AF undergoing TAVR, a population that warranted further study. In places such as East Asia where edoxaban is used, it remains a ...

4 Consideration of the evidence. The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of edoxaban, having considered evidence on the nature of non‑valvular atrial ...

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial ...

Male patients made up 51.3% and 62.4% of the edoxaban and warfarin arms, respectively. About one in five patients had AF, and the vast majority of patients had aortic valve surgery. About one-third of ...

"Edoxaban could make life easier for patients recovering from heart valve surgery," said study leader Dr. Chisato Izumi, of the National Cerebral and Cardiovascular Center in Suita, Japan.